Macular telangiectasia type 1
MONDO:0018146A rare, acquired, macular telangiectasia characterized by unilateral (rarely bilateral) abnormally dilated and tortuous capillaries around the fovea, associated with multiple arteriolar and venular aneurysms, lipid depositions, and intra-retinal cystoid degeneration. It leads to vision loss due to macular edema with hard exudates.
Also known as: aneurysmal telangiectasia, idiopathic macular telangiectasia type 1, visible and exudative idiopathic juxtafoveolar retinal telangiectasis
10 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Eye drug trial for rare macular disease stops early – only 16 patients enrolled
Disease control TerminatedThis phase 3 trial tested aflibercept (Eylea) eye injections against placebo in 16 people with macular telangiectasia type 1, a rare condition that causes vision loss. The study aimed to see if aflibercept could reduce swelling in the macula. However, the trial was terminated ear…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
VR headsets tested as a possible treatment for blindness
Disease control TerminatedThis study tested whether using a virtual reality headset for one-hour sessions could help regenerate damaged optic nerves and improve vision in people with glaucoma or other retinal diseases. The idea came from promising results in rodents. However, the trial was terminated earl…
Phase: NA • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC